Start Time: 16:30 January 1, 0000 5:23 PM ET

Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Q2 2023 Earnings Conference Call

August 10, 2023, 16:30 PM ET

Company Participants

Raju Mohan - Founder and CEO

Marty Auster - CFO

Bill Sandborn - President and Chief Medical Officer

Conference Call Participants

Michael Yee - Jefferies

Alex Thompson - Stifel

Vikram Purohit - Morgan Stanley

Derek Archila - Wells Fargo

Chris Shibutani - Goldman Sachs

Emily Bodnar - H.C. Wainwright

Sam Slutsky - LifeSci Capital

Operator

Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Second Quarter 2023 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode, and the floor will be open for your questions following the presentation. [Operator Instructions]. As a reminder, this conference call is being recorded.

I would now like to turn the call over to Dr. Marty Auster, Ventyx's Chief Financial Officer. Sir, you may begin.

Marty Auster

Thank you. Good afternoon, everyone. Welcome to Ventyx’s Biosciences conference call and webcast where we will be discussing our second quarter 2023 financial results and providing a business update for you. As a reminder, the company's most recent investor presentation can be found on our website at www.ventyxbio.com, under the Investors News & Events section.

Before we begin today, I’d like to remind everyone that this conference call and webcast will contain forward-looking statements about the company including without limitation statements about the anticipated timing of commencement, enrollment and completion of clinical trials for our product candidates, the anticipated timing of release of clinical trial data, the market opportunity for our product candidates and the expected timeframe for funding operations with our current cash, cash equivalents and marketable securities.

These statements are subject to risks and uncertainties that could cause actual results to differ. Factors that could cause actual results or outcomes to differ materially from those expressed and/or implied by such forward-looking statements are discussed in greater detail in our most recent periodic reports filed with the SEC, including our Form 10-Q for the quarter ended June 30, 2023, which I filed just a few minutes ago.

Please note that these forward-looking statements reflect our opinions only as of the date of this call and we undertake no obligation to revise or publicly release the results of any revisions to these forward-looking statements in light of new information or future events, except as required by law.